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Abstract
Background: Previous research has shown a potential link between antibiotic use among foodproducing animals and antimicrobial resistant enteric pathogens. In late 2016, the Food and Drug
Administration completed the implementation of its Guidance for Industry #213, through which
growth promotion was removed as an indication for use of medically-important antimicrobials
among food-producing animals. This study aimed to describe trends in antimicrobial resistance
among human Salmonella isolates from 2013-2020 in the United States before and after the
implementation of this regulation.
Methods: All non-Typhoidal Salmonella isolates sent to the National Antimicrobial Resistance
Monitoring System for Enteric Bacteria (NARMS) from 2013-2020 were included in this study
(n=16,183). Thirteen antibiotics were tested by NARMS for the years included in this study. The
Pearson’s chi-squared test and the Fisher’s exact test were used to evaluate differences in
proportion of resistant isolates for thirteen antibiotics. Median-unbiased odds ratios were
calculated for the change in proportion of isolates resistant to different antibiotic classes. Trends
in resistance were assessed using the Cochran-Armitage trend test.
Results: A significant decrease was observed in the proportion of isolates resistant to ampicillin
(p<0.001) and streptomycin (p<0.001), while an increase was observed for chloramphenicol
(p=0.002), nalidixic acid (p=0.001) and SMX-TMP (p<0.001). Isolates from 2017-2020 had a
lower likelihood of being resistant to at least one aminoglycoside (OR=0.69, 95% CI 0.62-0.76),
penicillin (OR=0.80, 95% CI 0.72-0.88), or sulfonamide (OR=0.87, 95% CI 0.79-0.96)
antibiotic, though a higher likelihood of being resistant to chloramphenicol (OR=1.28, 95% CI
1.09-1.50) or at least one fluoroquinolone (OR=1.97, 95% CI 1.72-2.27). Significant (p<0.05)
decreasing trends over 2013-2020 were observed for aminoglycosides, penicilins, and
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sulfonamides, while there was an increase in resistance over time to amphenicols,
fluoroquinolones, and macrolides.
Conclusion: Though likelihood of resistance to some antibiotics has decreased since the
implementation of GFI #213, there are still concerning trends in antibiotic resistance among
Salmonella. As more data become available from isolates after implementation, further research
is needed to better understand the impact of these regulatory changes.
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Introduction
Non-Typhoidal Salmonella enterica infections are one of the leading causes of foodborne
illness in the United States, causing an estimated 1.35 million infections per year, resulting in
thousands of hospitalizations and hundreds of deaths1. While many patients recover from
Salmonella infections without needing treatment, antibiotics are often prescribed for patients at
higher risk of complications or experiencing severe outcomes. As is the case for many other
pathogens, antimicrobial-resistant (AMR) Salmonella infections have been increasing in
frequency during recent decades. Surveillance data has shown a 40% increase in annual
incidence of non-Typhoidal Salmonella infections with clinically important antibiotic resistance
during the 2015-2016 period, versus the period between 2004 and 20082. Compared to antibioticsusceptible infections, AMR Salmonella infections have been associated with worsened clinical
outcomes (e.g., higher rates of hospitalization and longer hospital stays), higher rates of
complications (e.g., bacteremia), and millions of additional dollars in medical expenditures3.
Additionally, antimicrobial resistance among Salmonella poses a broader public health threat
through the potential for horizontal transfer of antimicrobial resistance genes, whereby genetic
elements coding for AMR are directly transferred from Salmonella to other bacterial organisms
in the environment.
Food-producing animals are a primary source of non-Typhoidal Salmonella infections in
humans1. Historically, the majority of medically important antibiotics in the U.S. have been sold
for use in animal agriculture (rather than use in humans), both for therapeutic and nontherapeutic reasons4. Antibiotics are given to food-producing animals to treat diagnosed or
suspected infection, or to prevent infection in high-risk settings. Prior to 2017, antibiotics could
also legally be used for growth promotion, in which antibiotics are given over a long period of
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time at sub-therapeutic doses to increase body mass of food-producing animals. For multiple
reasons, agricultural usage of antibiotics can promote the development of AMR. Due to the
nature of administering medication to food-producing animals (typically through feed or water),
far more animals than necessary are exposed to the compound. Functionally, this produces the
same effects as intentionally giving animals unwarranted antibiotics, an action that is
inconsistent with good antibiotic stewardship. Growth promotion and some prophylactic use of
antibiotics among food-producing animals include long-term, low-dose courses that exert
selective pressure on bacterial populations in a manner that promotes resistance5. There is
substantial overlap between the antibiotic classes used in food-producing animals and those used
to treat human infections, though the exact compounds used in human medicine often vary from
those used in animal agriculture. The FDA reports that prior to 2017, substantial amounts of
medically-important antimicrobial compounds (antibiotics classified by the FDA as important for
human therapy) were sold for both production and non-production uses in animal agriculture6.
Tetracyclines (chlortetracycline, oxytetracycline, and tetracycline) by far compromised the
greatest proportion of antibiotic sales, followed by penicillins (amoxicillin, ampicillin,
cloxacillin, and penicillin), macrolides (gamithromycin, tildipirosin, tilmicosin, tulathromycin,
tylosin, and tylvalosin), and aminoglycosides (dihydrostreptomycin, gentamicin, neomycin,
spectinomycin).
Data have shown that a relationship between agricultural antibiotic use and antibiotic
resistance among Salmonella is likely. Compared to reduced-antibiotic poultry meats,
conventional poultry meats are more likely to harbor drug-resistant Salmonella7. Multiple
pathogens, including Salmonella, have been shown to exhibit increased resistance to ampicillin,
tetracycline, and nalidixic acid (antibiotics used to treat human infections) after being exposed to
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sub-inhibitory concentrations of tilmicosin and florfenicol, two antibiotics commonly used in
animal feed8. In addition to transmission directly through food, antibiotics used in agriculture
have runoff effects for the surrounding environment. For example, higher concentrations of
AMR Salmonella, with particularly high levels of sulfamethoxazole-resistant organisms, have
been noted in the environment surrounding pig-rearing facilities9. Not all AMR in Salmonella
can be attributed to food-producing animals; the diversity of resistance genes and patterns is
greater among human bacterial isolates than with isolates obtained from retail meats and foodproducing animals, suggesting alternate sources of resistance10. Even so, use of antibiotics in
agriculture appears to influence the prevalence of antibiotic resistance among human infections,
though the extent to which this occurs is controversial. A 2017 meta-analysis commissioned by
the World Health Organization revealed that interventions (e.g., externally-imposed restrictions
or voluntary reductions) restricting antimicrobial use in animal agriculture reduced prevalence of
antibiotic resistance among bacterial pathogens isolated from food-producing animals by ~1015% and from humans by ~24%11.
In response to these concerns, the federal government has taken action to address the use
of medically important antimicrobials in animal agriculture. The bulk of these changes began
with Guidance for Industry #209 (GFI #209), issued by the Food and Drug Administration
(FDA) in April 2012. The document outlined the FDA’s concerns regarding antibiotic use in
agriculture, as well as action that should be taken to mitigate the issues12. Guidance for Industry
#213 (GFI #213) built upon GFI #209 by providing a timeline with specific steps to reach the
goals outlined in GFI #209. The key action from this plan was to work with drug sponsors of
medically important antimicrobials used in food-producing animals to shift these drugs to
Veterinary Feed Directive (VFD) or prescription-only, and to remove growth promotion as an
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indication for use13. Additionally, in 2015, while GFI #213 was in the process of being
implemented, the FDA made changes to their VFD rule to require that VFDs only be given in the
context of a legitimate veterinarian-patient-client relationship, further promoting judicious use of
antibiotics14. In January 2017, the FDA announced that the implementation of GFI #213 had
been completed in late 2016, effectively prohibiting the use of antibiotics for growth promotion
purposes.
These regulatory changes appear to have had some effect on the agricultural use of
antibiotics. According to the FDA, there was a substantial decrease (for all drug classes except
for aminoglycosides) in the quantities of medically-important antibiotics sold for veterinary use
in food-producing animals use beginning in 2017 compared to 20166. Sales of all antibiotic
classes decreased from 2016 to 2017 except for fluoroquinolones (sales of which continued to
rise until 2019) and lincosamides (sales of which increased from 142,458 kg2 in 2016 to 152,497
kg2 in 2017, then briefly dropped to 125,514 kg2 before increasing again). Most notably, sales of
tetracyclines decreased from 5,861,118 kg2 in 2016 to 3,535,701 kg2 in 2017. Overall, sales of all
medically-important antibiotics decreased from 8,356,340 kg2 in 2016 to 5,559,215 in 2017.
Furthermore, additional studies have evaluated the impact of these regulatory changes on
farming practices. A survey of poultry farmers revealed a substantial reduction in antibiotic use
in chicken hatcheries from 2013 to 201715. Cattle farmers in Ohio interviewed after the
implementation of GFI #213 largely stated that their antibiotic use had decreased as a result of
the new regulations16. While it is unclear to what extent widespread changes in antibiotic usage
during this time period can be attributed directly (e.g., through revocation of approval for certain
antibiotic indications) or indirectly (e.g., through changing common perception of antibiotic use
among the agricultural industry) to these federal regulatory changes, they do appear to have had
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a substantial impact on farming practices. Nevertheless, concerns have been raised that these
regulations are insufficient. There is great overlap between antimicrobials used for disease
prevention and those used for growth promotion among food-producing animals; agricultural
producers may therefore use antimicrobials for growth promotion under the guise of disease
prevention, with no beneficial change in how the drug is used17. Additionally, these regulations
do not address the unsanitary conditions in animal rearing facilities (e.g., overcrowding) that
often underly the need for prophylactic antibiotics.
The National Antimicrobial Resistance Monitoring System for Enteric Bacteria
(NARMS), a collaborative effort between the Centers for Disease Control (CDC), Food and
Drug Administration (FDA), and United States Department of Agriculture (USDA) performs
surveillance of AMR among enteric pathogens isolated around the country. Thus far, there has
been limited research concerning the impact of GFI #213 on the prevalence of antimicrobial
resistance within foodborne pathogens, particularly for human infections. The objective of this
analysis is to describe trends in antimicrobial resistance of Salmonella infections in the U.S. from
2013-2020 and examine whether these trends have changed since the implementation of GFI
#213 in late 2016. This information is important for assessing our progress in one aspect of
turning the tide for antimicrobial resistance, both for Salmonella and more broadly.
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Methods
Data Source
Human non-Typhoidal Salmonella isolate data were obtained from NARMS. State public
health laboratories nationwide perform initial testing on clinical samples associated with human
infections, and each twentieth isolate of Salmonella isolates are sent to the CDC for further
testing as part of the NARMS program18. When isolates are selected, state officials enter
metadata for each isolate through a CDC NARMS Database interface. From 2013 to 2020, the
years included in this study, antibiotic susceptibility testing of Salmonella isolates was
consistently performed by NARMS for the following antimicrobial agents19:
•

Aminoglycosides: gentamicin and streptomycin

•

Amphenicols: chloramphenicol

•

Cephalosporins: cefoxitin and ceftriaxone

•

Fluoroquinolones: ciprofloxacin and nalidixic acid

•

Macrolides: azithromycin

•

Penicillins: ampicillin and amoxicillin-clavulanic acid

•

Sulfonamides: sulfamethoxazole-trimethoprim (SMX-TMP) and sulfisoxazole

•

Tetracyclines: tetracycline

These results are then uploaded to the NARMS database18. NARMS categorizes isolates as
susceptible, intermediate, or resistant to an antibiotic based on Clinical and Laboratory Standards
Institute (CLSI) established breakpoints19. While additional antibiotics have been tested by
NARMS at some point in the program’s history, they have not been consistently tested during
the years included in this analysis. In addition to antimicrobial susceptibility testing results,
NARMS provides Department of Health and Human Services (DHHS) region, age group of the
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patient (0-4, 5-9, 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80+), and specimen source for
the isolate.
All non-typhoidal human Salmonella isolates submitted to NARMS from various
specimen sources collected from 2013 to 2020 across the U.S. were used in this analysis. Cases
of typhoid (caused by S. Typhi) and paratyphoid (S. Paratyphi A, tartrate negative S. Paratyphi B,
and S. Paratyphi C) fever were excluded, as these infections are most commonly associated with
travel to endemic areas. Isolates from 2017 to 2020 were used to assess outcomes after the
implementation of GFI #213, which was completed by the beginning of 2017. Data from the
previous four-year period were used as a comparison. All information used in this study was deidentified and open-access, thus institutional review board approval was not required.

Data Analysis
Isolates were divided into time categories based on their year of specimen collection as
either before (2013-2016) or after (2017-2020) the completed implementation of GFI #213.
To maintain consistency, given that no intermediate range of susceptibility has been identified
for some antibiotics tested by NARMS, isolates considered to have “intermediate” susceptibility
were grouped with susceptible isolates. Isolates were classified as being multidrug-resistant
(MDR) if they were resistant to at least one antimicrobial from three or more classes (per CDC
definition)20. Broader age groups (0-4, 20-59, 60+) were used to account for heightened risk of
salmonellosis among children under 5 and severe outcomes in older adults. When grouping
isolates into resistance by class, 2020 observations were removed for aminoglycosides, as
susceptibility data for one of the two aminoglycoside antibiotics were missing for 2020.
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The Pearson’s chi-squared test was used to evaluate association between time period and
characteristics of isolates (specimen source, DHHS region, and age group). The Bonferroni
method was used to calculate adjusted p-values for post-hoc tests. The Pearson’s chi-squared test
(for all antibiotics except for azithromycin) was used to evaluate change in the proportion of
antibiotics resistant to a given antibiotic after 2016. The Fisher’s exact test was used in lieu of
chi-squared for azithromycin, as very few isolates in this study exhibited azithromycin
resistance. For this analysis only, based on the Bonferroni method for multiple comparisons,
results with a p-value of under 0.004 (rather than 0.05) were considered significant.
Median unbiased odds ratios were determined for the likelihood of an isolate being
resistant to at least one antibiotic in a given class and for the likelihood of an isolate being
resistant to both antibiotics in that class (if NARMS tests multiple antibiotics in that class).
Annual change in percentage of isolates resistant to each tested antimicrobial agent and class was
calculated starting from the 2012-2013 difference to the 2019-2020 difference; the mean annual
chance was calculated for the period before and after GFI #213. The Cochran-Armitage trend
test was used to assess trends in proportion of resistance for the entire 2013-2020 time period, as
well as separately for the 4-year periods before and after the implementation of GFI #213. Pvalues of under 0.05 were considered significant. All analyses were performed using RStudio
Version 1.3.1093.
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Results
Characteristics of Isolates
A total of 16,183 isolates were included in this study. Table 1 summarizes the
characteristics of these isolates. Significant changes were observed for all three isolate
characteristics assessed: specimen source, age group, and DHHS region. The proportion of
isolates obtained from stool samples decreased from 85% in 2013-2016 to 82% in 2017-2020,
while the percentage of isolates obtained from urine samples increased from 5.5% to 6.4%. The
proportion of isolates obtained from blood or other specimen types remained relatively constant
between each period. The percentage of isolates from the 60+ year age group increased from
23% to 28%, while the proportion of isolates from the 0-4 year (21% to 19%) and 5-59 year
(56% to 52%) age groups decreased. Significant changes were also observed for the proportion
of isolates obtained from certain DHHS regions. An increase was observed for Region 9 (8.9%
to 14%), while significant decreases were observed for Region 1 (4.2% to 3.3%) and Region 3
(4.2% to 3.3%). The greatest proportions of isolates (during both time periods) were from
Regions 4, 5, and 6.

Proportions of Antimicrobial-Resistant Isolates
Of all antibiotics tested, isolates were most likely to be resistant to tetracycline (13% of
isolates in 2013-2016 and 12% of isolates in 2017-2020), and least likely to be resistant to
azithromycin (fewer than 0.1% of samples in each time period). Changes in proportion of
isolates resistant to individual antibiotics were observed for seven of the thirteen antibiotics
tested by NARMS (Table 2). Ampicillin resistance decreased from 11% of isolates in the 2013 to
2016 time period to 9.1% in the 2017-2020 period (p<0.001) and streptomycin (13% to 9.1%,
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p<0.001). Conversely, statistically significant increases were observed for three antibiotics:
chloramphenicol (3.8% to 4.8%, p=0.002), nalidixic acid (3.9% to 7.4%, p<0.001), and SMXTMP (1.7% to 2.6%, p<0.001). Though at the 0.05 significance level there was a change in
ceftriaxone (2.9% to 2.4%, p=0.048) and sulfisoxazole (11% to 9.1%, p=0.009), these changes
were no longer significant after Bonferroni correction. No significant changes were observed for
other antibiotics or for the proportion of isolates resistant to at least one antibiotic.
The likelihood of isolates being resistant to one (OR=0.69, 95% CI 0.62-0.76) or both
(OR=0.61, 95% CI 0.45-0.82) aminoglycosides was lower after 2016 (Table 3). While there was
a significant decrease in the likelihood of resistance to one or more penicillins (OR=0.80, 95%
CI 0.72-0.88) and sulfonamides (OR=0.87, 95% CI 0.79-0.96), the same pattern was not
observed for resistance to both antibiotics within each of those classes. Conversely, isolates from
2017-2020 were more likely (OR=1.56, 95% CI 1.26-1.95) to be resistant to both sulfonamides.
After 2016, isolates were more likely (OR=1.28, 95% CI 1.09-1.50) to be resistant to
chloramphenicol. Similarly, likelihood of resistance to at least one fluoroquinolone increased
(OR=1.97, 95% CI 1.72-2.27) for the later time period. There was no statistically significant
change in odds of multidrug-resistance after 2016.

Trends in Resistance
2015 saw the highest percentage of isolates with resistance to one or more
aminoglycosides, penicillins, sulfonamides, and tetracycline (Figure 1). Fluoroquinolone
resistance peaked in 2019. Amphenicol and cephalosporin resistance remained relatively low and
stable over time, reaching their maximums in 2019 and 2018, respectively. The mean annual
change decreased after 2016 for aminoglycosides, penicillins, and sulfonamides; individually,
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the mean decreased for streptomycin, ciprofloxacin, amoxicillin-clavulanic acid, ampicillin, and
sulfisoxazole. Conversely, the mean increased for amphenicols (chloramphenicol),
cephalosporins, fluoroquinolones, and tetracyclines (tetracycline); there was an individual
increase for gentamicin, cefotixin, ceftriaxone, nalidixic acid, and SMX-TMP.
During the overall study period (2013-2020), there was a significant decreasing trend for
resistance to aminoglycosides (p<0.001), penicilins (p<0.001) and sulfonamides (p=0.001),
while there was an increase in resistance over time to amphenicols (p=0.009), fluoroquinolones
(p<0.001), and macrolides p=0.009). There was no significant trend in cephalosporins and
tetracyclines over time (Table 5). When split into individual antibiotics, there was some
discordance with trends for certain antibiotic classes. A decreasing trend was observed for
gentamicin (p=0.005), streptomycin (p<0.001), cefoxitin (p=0.029), ampicillin (p<0.001), and
sulfisoxazole (p=0.001). An increasing trend was observed for ceftriaxone (p=0.046), nalidixic
acid (p<0.001), and SMX-TMP (p<0.001). No significant trend was observed for ciprofloxacin,
amoxicillin-clavulanic acid, and tetracycline. For some antimicrobials and classes there was
discordance between the overall trends and the trends for each four-year period. Table 5
summarizes these results.
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Discussion
Substantial changes in the likelihood of Salmonella resistance were observed for many
antibiotics and classes of antibiotics after the completion of GFI #213’s implementation in late
2016. It is unclear, however, to what extent these changes can be attributed to the regulation.
Differences in likelihood of resistance between the two four-year periods may be partially
attributable to the overall trends during 2013-2020 (which was observed for several antibiotics
and classes of antibiotics). This window of time saw increased awareness of the threats
associated with antimicrobial resistance and increased urgency towards combatting it, reflected
by the CDC publishing its first Antibiotic Resistance Threats Report in 2013. Consumers of
animal-based food products have been shown to be conscious of antibiotics when making
purchases, which has driven demand for poultry products labeled as organic or raised without
antibiotics6. Additionally, some changes in agricultural operations likely occurred before
implementation was completed in late 2016.
Differences in mean annual change in resistance between the four-year periods, in addition to
discordance between overall trends and four-year trends, suggest that for some antibiotics, a
decrease or increase in proportion of resistant organisms either began or accelerated after 2016.
For three out of seven antibiotic classes, and for six out of thirteen individual antibiotics, the
mean annual change in resistance was less during the latter time period (either switched from
positive to negative change or decreased by a greater amount per year). Differences in four-year
trends before and after (at which time significant trends were only found for a few antibiotics and
classes) GFI #213 suggest that changes in antibiotic resistance between years were not consistent
throughout the study period. It is therefore possible that there were changes in antibiotic
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resistance before and after the implementation of GFI #213 independent of overall trends in the
past decade.
Based on the FDA Summary Report, it is clear that sales of medically important
antimicrobials decreased substantially from 2016 to 2017. The results of this study suggest that
for some antibiotics, these changes may be associated with lower rates of resistance in human
Salmonella isolates, particularly for penicillins, aminoglycosides, and sulfonamides. However,
there was a notable increase in fluoroquinolone and amphenicol resistance, and a lack of change
for tetracycline (despite having the greatest volume of sales among antibiotic classes and the
greatest drop in sales after 2016) and cephalosporin resistance. For several reasons, the
proportion of resistance among human isolates may remain stable or increase despite reduction
in agricultural antibiotic use. While some resistance mechanisms that are advantageous in the
presence of antibiotics may present a fitness cost to Salmonella, this is not the case for all
mechanisms; resistance may therefore remain prevalent in the population even with less
exposure to antibiotics. Additionally, AMR Salmonella may be imported from abroad. In
Australia, for example, fluoroquinolones have never been approved for use in food-producing
animals, though a substantial proportion of isolates from Australian human Salmonella cases
from 1979 to 2015 exhibited fluoroquinolone resistance21. The authors of this study note that
many of the fluoroquinolone-resistant Salmonella isolates from Australian cases were associated
with international travel.
It is also possible that GFI #213 has not sufficiently reduced agricultural antibiotic use.
Further action may be needed to ameliorate antimicrobial resistance among foodborne bacteria
associated with food-producing animals. The regulatory changes of GFI #213 may allow for too
many “loopholes” as agricultural producers may increase their use of antibiotics for proclaimed
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preventive reasons. The 2020 FDA report did in fact show a marked increase in sales of
antimicrobials used for therapeutic (i.e. disease prevention and treatment) purposes in 2017,
suggesting that producers may be using antibiotics for production purposes under a different
label6. In 2018 the State of California passed a bill to further regulate preventive use of
antibiotics, which can serve as a model for further regulations at the federal level22.
These results also have implications for the treatment of clinical disease in humans. The
Infectious Diseases Society of America recommends azithromycin or fluoroquinolones for
patients with suspected bacterial gastroenteritis when certain risk factors are present23. While
azithromycin resistance among Salmonella remains exceptionally uncommon (seen in less than
0.1% of isolates in this study), azithromycin-resistant Salmonella Newport has been implicated
in a multidrug-resistant outbreak, and serves as a reminder of the importance of combatting
azithromycin resistance in Salmonella24. The increase in the proportion of isolates resistant to
fluoroquinolones is concerning, though very few isolates have shown resistance to azithromycin,
providing a viable treatment option for many cases in which antibiotics are warranted.
Ciprofloxacin is the most commonly used fluoroquinolone antibiotic for Salmonella; fortunately,
among these isolates, those determined to be resistant were uncommon. However, this study did
not account for intermediate susceptibility, which for ciprofloxacin has been associated with
poor treatment outcomes2. Third generation cephalosporins (most commonly ceftriaxone) are
often used for empiric treatment of severe infections2. Compared to most other classes of
antibiotics, the proportion of isolates resistant to cephalosporins remained relatively low, there is
still some concern posed by the overall increasing trend of ceftriaxone resistance seen in this
analysis.
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The distribution of specimen sources, age groups, and DHHS region all had significant
changes between the two time periods. Though patients who test positive for Salmonella at a
different site may also harbor the bacteria in their gastrointestinal tract, the site of collection may
have some association with whether a patient’s infection is related to foodborne transmission.
Some gene clusters that code for virulence of Salmonella have been found to be strongly
associated with resistance phenotypes25. Consequentially, it is possible that age may serve as a
confounder, given that severe salmonellosis is more likely to occur in those under five years of
age and elderly individuals. Additionally, the food intake of young children (and thus their
foodborne pathogen exposures) typically differs from that of older individuals. There may be
some regional differences (e.g., different population demographics, climate, or local farming
practices) associated with the DHHS region for an isolate; however, due to the interconnected
nature of the U.S. food system, it is not uncommon for outbreaks of Salmonella to affect areas
around the country.
This study was substantially limited in that only four years of data were available after
the implementation of GFI #213. Analysis of trends and changes in these trends will become
more reliable as additional years of data become available. Ideally, with more years of data
available, isolates from immediately before and after implementation was completed could be
omitted to account for a delay in the impact of regulations on AMR. The dataset used presented
many inherent challenges. Availability of specific dates of collection (rather than year of
collection) would allow for a better understanding of how, and how quickly, these trends are
changing, particularly through modelling approaches. With better availability of whole genome
sequencing data (the consistency of which was lacking in this study, particularly for samples
from earlier years), it may be possible to link human infection samples to food sources (samples
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of which are collected by the FDA for NARMS) and assess specific resistance mechanisms. The
samples tested by NARMS may not be entirely representative of all non-Typhoidal Salmonella
infections in the U.S., as NARMS only tests a subset of reported salmonellosis cases.
Additionally, many patients with Salmonella infections do not seek medical care (either due to a
lack of symptom severity or a lack of access to medical care). Given a potential relationship
between virulence and AMR among Salmonella, and the fact that those with severe illness are
more likely to seek testing and treatment, there may be a higher proportion of AMR organisms
among the isolates sent to NARMS compared to the broader population of human Salmonella
isolates. An additional consideration is the ongoing COVID-19 pandemic, which caused many
healthcare services to transition to telehealth; isolates from 2020 may be more likely (compared
to other years) to originate from patients ill enough to require in-person hospital care.
As more data becomes available from the years after 2017, further research is needed to
better understand the impacts of this regulation and similar changes on the prevalence of
antibiotic resistance among human Salmonella infections. Similar studies should also be
performed with other pathogens (e.g., Campylobacter, E. coli) typically associated with foodproducing animals to better understand the impact of this regulation on antimicrobial resistance
in other foodborne pathogens. Better data concerning use (rather than sales) of specific
antimicrobial agents (which are grouped by antibiotic class in the FDA’s Summary Report)
would allow for further analysis of how antibiotic use correlates with antibiotic resistance among
human Salmonella infections. Further research concerning this relationship, and how this
relationship changes with legal interventions such as GFI #213 is crucial for mitigating a current
and worsening public health threat and to lessen morbidity and mortality from antimicrobialresistant foodborne illness.
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Table 1. Characteristics of included Salmonella isolates.
The association between time period (either 2013-2016 or 2017-2020) with specimen source, age
group, and Department of Health and Human Services (DHHS) region was assessed using
Pearson’s chi-squared tests. The Bonferroni adjusted p-values are reported for each specimen
source, age group, and DHHS region.
Characteristic
Specimen Source
Stool
Urine
Blood
Other
Age Group
0-4
5-59
60+
3
DHHS Region
Region 1
Region 2
Region 3
Region 4
Region 5
Region 6
Region 7
Region 8
Region 9
Region 10

Before
(N=7,789)1

After
(N=8,394)1

p-value2

6,593 (85%)
432 (5.5%)
621 (8.0%)
143 (1.8%)

6,895 (82%)
537 (6.4%)
785 (9.4%)
177 (2.1%)

<0.01
0.01
0.18
1.00

1,667 (21%)
4,358 (56%)
1,764 (23%)

1,623 (19%)
4,396 (52%)
2,375 (28%)

<0.01
<0.01
<0.01

331 (4.2%)
705 (9.1%)
901 (12%)
1,360 (17%)
1,259 (17%)
1,313 (17%)
475 (6.1%)
328 (4.2%)
693 (8.9%)
324 (4.2%)

276 (3.3%)
723 (8.6%)
835 (9.9%)
1,344 (16%)
1,347 (16%)
1,476 (18%)
556 (6.6%)
340 (4.1%)
1,186 (14%)
311 (3.7%)

0.02
1.00
0.02
0.27
0.34
1.00
1.00
1.00
<0.01
1.00

1

N (%)
Bonferroni adjusted post-hoc p-values for Pearson’s chi-squared test
3
Department of Health and Human Services Regions: Region 1 (Connecticut, Maine, Massachusetts, New
Hampshire, Rhode Island, and Vermont); Region 2 (New Jersey , New York); Region 3 (Delaware, Maryland,
Pennsylvania, Virginia, West Virginia, Washington, D.C); Region 4 (Alabama, Florida, Georgia, Kentucky,
Mississippi, North Carolina, South Carolina, and Tennessee); Region 5 (Illinois, Indiana, Michigan, Minnesota,
Ohio, and Wisconsin); Region 6 (Arkansas, Louisiana, New Mexico, Oklahoma, and Texas); Region 7 (Iowa,
Nebraska, Missouri, and Kansas); Region 8 (Colorado, Montana, North Dakota, South Dakota, Utah, and
Wyoming); Region 9 (Arizona, California, Hawaii); Region 10 (Alaska, Idaho, Oregon, and Washington)
2
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Table 2. Number and proportion of Salmonella isolates resistant to antimicrobial agents tested by
NARMS before and after implementation of GFI #213 from 2013-2020.
Pearson’s chi-squared tests were performed to determine changes in the proportion of isolates
resistant to each antibiotic before and after the implementation of GFI #213 at the end of 2016.
For azithromycin, considering the low number of resistant isolates, the Fisher’s exact test was
used in lieu of chi-squared. As fourteen different tests performed, results with a p-value of
<0.004 (the threshold determined using Bonferroni correction for multiple comparisons) were
considered significant after adjustment.
Before
(N=7,789)
863 (11%)

After
(N=8,394)
762 (9.1%)

p-value1

AmoxicillinClavulanic Acid
Azithromycin

214 (2.7%)

198 (2.4%)

0.129

2 (<0.1%)

6 (<0.1%)

0.292

Cefoxitin

206 (2.6%)

191 (2.3%)

0.142

Ceftriaxone

224 (2.9%)

228 (3.4%)

0.048

Chloramphenicol

294 (3.8%)

402 (4.8%)

0.002

Ciprofloxacin

32 (0.4%)

39 (0.5%)

0.691

Gentamicin

128 (1.6%)

108 (1.3%)

0.068

Nalidixic Acid

300 (3.9%)

624 (7.4%)

<0.001

SulfamethoxazoleTrimethoprim
Sulfisoxazole

133 (1.7%)

220 (2.6%)

<0.001

840 (11%)

800 (9.5%)

0.009

Streptomycin

1,010 (13%)

760 (9.1%)

<0.001

Tetracycline

975 (13%)

1,014 (12%)

0.410

Resistance to 1+
Antibiotic

1,605 (21%)

1,712 (20%)

0.755

Antibiotic
Ampicillin

<0.001
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Table 3. Resistance to different antibiotic classes before and after implementation of GFI #213
Median-unbiased odds ratios were calculated to determine if isolates from the 2017-2020 time
period had a significantly higher likelihood of being resistant to at least one or (where
applicable) both antibiotics from a given class when compared to isolates from 2013-2016.
Antibiotic Class
Aminoglycosides
Amphenicols
Cephalosporins
Fluoroquinolones
Macrolides
Penicillins
Sulfonamides
Tetracyclines
3+ Classes

Resistance to 1+ Agent
0.69 (0.62 - 0.76)
1.28 (1.09 - 1.50)
1.16 (0.98 – 1.39)
1.97 (1.72 – 2.27)
2.65 (0.59 – 20.06)
0.80 (0.72 – 0.88)
0.87 (0.79 – 0.96)
0.96 (0.87 – 1.05)
0.90 (0.81 – 1.01)

Resistance to Both Agents
0.61 (0.45 - 0.82)
N/A
0.88 (0.72 – 1.08)
1.30 (0.80 – 2.16)
N/A
0.86 (0.70 – 1.04)
1.56 (1.26 – 1.95)
N/A
N/A
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Table 4. Mean annual change of percentage of resistant isolates by antibiotic and class before
and after implementation of GF1 #213
The mean annual change in percentage of isolates resistant to each antibiotic and antibiotic class
was calculated for each time period, beginning with the change from 2012 to 2013 and ending
with the change from 2019 to 2020.
Antibiotic Class

Antibiotic

Aminoglycosides
Amphenicols
Cephalosporins

Gentamicin
Streptomycin
Chloramphenicol
Cefoxitin
Ceftriaxone

Fluoroquinolones
Ciprofloxacin
Nalidixic Acid
Macrolides*
Penicillins
AmoxicillinClavulanic Acid
Ampicillin
Sulfonamides

Tetracyclines

SulfamethoxazoleTrimethoprim
Sulfisoxazole
Tetracycline

Mean Annual
Change 2013-2016
+ 0.799
- 0.046
+ 0.851
- 0.228
- 0.023
+ 0.026
- 0.035
+ 0.426
+ 0.035
+ 0.402

Mean Annual
Change 2017-2020
- 0.022
+ 0.218
- 0.150
+ 0.454
+ 0.117
+ 0.052
+ 0.129
+ 0.856
- 0.026
+ 0.856

+ 0.229
- 0.048

- 0.350
- 0.143

+ 0.229
+ 0.117
+ 0.013

- 0.350
- 0.294
+ 0.251

+ 0.168
+ 0.074

- 0.294
+ 0.109

*Omitted due to less than 0.1% of isolates having resistance to azithromycin.
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Table 5. Trends in antibiotic resistance by antibiotic and class
The Cochran-Armitage trend test was performed to determine the presence of increasing or
decreasing trends in proportion of resistant isolates for each antibiotic and antibiotic class. The
test was performed for the overall trend (2013-2020) as well as for each time period (2013-2016
and 2017-2020).
Antibiotic Class

Antibiotic

Aminoglycosides

Gentamicin
Streptomycin
Chloramphenicol

Amphenicols
Cephalosporins

Cefoxitin
Ceftriaxone

Fluoroquinolones

Ciprofloxacin
Nalidixic Acid
Azithromycin

Macrolides
Penicillins

Sulfonamides
Tetracyclines

AmoxicillinClavulanic Acid
Ampicillin
SulfamethoxazoleTrimethoprim
Sulfisoxazole
Tetracycline

Overall
Trend
Decreasing
Decreasing
Decreasing
Increasing
No trend
Decreasing
Increasing
Increasing
No trend
Increasing
Increasing
Decreasing

2013-2016
Trend
No trend
Decreasing
No trend
Decreasing
No trend
No trend
No trend
Increasing
No trend
Increasing
Increasing
No trend

2017-2020
Trend
Decreasing
No trend
No trend
No trend
No trend
No trend
No trend
Increasing
No trend
Increasing
Increasing
No trend

No trend

No trend

No trend

Decreasing
Decreasing

No trend
No trend

No trend
No trend

Increasing

No trend

No trend

Decreasing
No trend

No trend
No trend

No trend
No trend
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Figure 1. Percentage of isolates with resistance to different antibiotic classes over time.
Maximum percentage of isolates with resistance to one or more aminoglycosides (green),
penicillins (purple), sulfonamides (yellow), and tetracycline (brown) was seen in 2015.
Fluoroquinolone (blue) resistance peaked in 2019. Amphenicol and cephalosporin resistance
remained relatively low and stable over time, though reached their maximums in 2019 and 2018,
respectively. Macrolide resistance was omitted due to less than 0.1% of isolates being resistant to
azithromycin.
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